JNJ Stock Analysis: Q2 2026 Growth, Stelara Pressure and Dividend Coverage
This JNJ stock analysis focuses on the business transition behind Johnson & Johnson’s Q2 2026 results rather than short-term price targets or technical support levels. The company reported $25.310 billion of quarterly sales, up 6.6% year over year, while adjusted diluted EPS increased 4.7% to $2.90. The more important story is inside the two operating … Read more